KR930703434A - 사람 간세포-함유 조성물의 배양방법 및 형질전환 방법 - Google Patents

사람 간세포-함유 조성물의 배양방법 및 형질전환 방법

Info

Publication number
KR930703434A
KR930703434A KR1019930701843A KR930701843A KR930703434A KR 930703434 A KR930703434 A KR 930703434A KR 1019930701843 A KR1019930701843 A KR 1019930701843A KR 930701843 A KR930701843 A KR 930701843A KR 930703434 A KR930703434 A KR 930703434A
Authority
KR
South Korea
Prior art keywords
cells
medium
human
hematopoietic
cell
Prior art date
Application number
KR1019930701843A
Other languages
English (en)
Other versions
KR100225307B1 (ko
Inventor
지. 에머슨 스테펜
에프. 클라크 마이클
오. 팔슨 버언하드
엠. 슈바르츠 리챠드
Original Assignee
로버트 엘. 로브
리전츠 오브 더 유니버시티 오브 미시간
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로버트 엘. 로브, 리전츠 오브 더 유니버시티 오브 미시간 filed Critical 로버트 엘. 로브
Publication of KR930703434A publication Critical patent/KR930703434A/ko
Application granted granted Critical
Publication of KR100225307B1 publication Critical patent/KR100225307B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/34—Internal compartments or partitions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/04—Filters; Permeable or porous membranes or plates, e.g. dialysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
    • C12M29/10—Perfusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
    • C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0642—Granulocytes, e.g. basopils, eosinophils, neutrophils, mast cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/38—Hormones with nuclear receptors
    • C12N2501/39—Steroid hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1394—Bone marrow stromal cells; whole marrow
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/99—Coculture with; Conditioned medium produced by genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Abstract

본 발명에서는 생체와 사람 간 세포 분할 및 안정한 유전적 형질전환 및/또는 사람 조혈 선구 세포 배양의 최적화 및/또는 사람 간질 세포의 대사 또는 GM-CSF 분비 또는 IL-6 분비의 증가를 제공하는 방법 및 배양 배지 조성물과 반응기가 개시된다.
상기 방법은 사람 간 세포 및/또는 사람 조혈 선구 세포 및/또는 사람 간질 세포를, 연속적으로 또는 주기적으로, 약 24시간 내지 48시간 주기동안 배양액 1ml 당 배지 1ml의 비유로 교체되는 액체 배지에서 배양하는 것과, 배양물을 생리적으로 허용되는 조건하에서 유지하면서 대사산물을 제거하고 고갈된 영양분을 보충하는 것을 토대로 한다.
이때 임의로 성장인자들이 배양 배지에 첨가된다.

Description

사람 간세포 - 함유 조성물의 배양방법 및 형질전환 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 관류 챔버의 개략도; 제2도는 관류 배지 경로의 흐름도 및 개략도; 제3a도는 세포의 분리를 위한 전단응력을 측정하기 위한 흐름챔버의 개략도; 제3b도는 제3a도의 흐름챔버의 측면도; 제3c도는 조혈세포에 대한 전단응력 프로필의 그래프도.

Claims (55)

  1. 사람 간세포를 함유하고 있는 세포조성물을 배양하여 사람 간세포 분할을 생체외에서 얻기 위한 방법으로서, 상기 세포 조성물을, 연속적으로 또는 주기적으로 약 24시간 내지 48시간 주기동안 배양액 1ml 당 약 1ml의 배지의 비유로 교체되는 액체 배지에서 배양하는 단계와, 상기 배양물을 생리적으로 허용되는 조건하에서 유지하면서 대사산물을 제거하고 고갈된 영양분을 보충하는 단계로 이루어지는 방법.
  2. 제1항에 있어서, 상기 배지가 연속적으로 교체되는 것을 특징으로 하는 방법.
  3. 제2항에 있어서, 상기 배지의 교체가 상기 사람 간세포 덩어리의 최소한 일부분을 통하여 새로운 배지를 관류시키는 것을 특징으로 하는 방법.
  4. 제1항에 있어서, 상기 배지가 주기적으로 교체되는 것을 특징으로 하는 방법.
  5. 제4항에 있어서, 상기 배지의 교체가 상기 사람 간세포 덩어리의 최소한 일부분을 통하여 새로운 배지를 관류시키는 것을 특징으로 하는 방법.
  6. 제1항에 있어서, 상기 배지가 조혈 배양 배지이고, 사람 말초 혈액 단핵 세포, 사람 골수세포, 사람 태아간(liver)세포 및 사람 코오드혈액 세포로 이루어지는 군으로부터 선택된 최소한 한가지가 배양되는 것을 특징으로 하는 방법.
  7. 제1항에 있어서, 반응기 용기내에서 팩킹이 점착하는 간질세포와 간세포를 포함하고 있는 사람 조혈 세포를 조합하여 상기 간질세포의 최소한 일부분이 형질전환되어, 상기 조혈세포의 증식, 분화, 또는 이들 두가지를 특징하는 최소한 하나의 성장인자를 분비할 수 있도록 하는 단계; 대사산물을 제고하고 고갈된 영양분을 보충하고, 생리적으로 허용되는 조건하에서 상기 반응기를 유지하면서, 영양배지가 들어있는 상기 반응기내에서 상기 세포의 계속 관류시키는 단계; 그리고 상기 반응기 용기 안으로 접종된 사람 조혈세포가 신생세포를 포함하고 있는 것으로 의심되는 경우, 상기 간질 세포에 대한 신생세포의 친화력보다 더 크고, 정상 조혈세포의 친화력보다 더 작은 힘을 제공하는 비율로 관류시키는 조건하에, 상기 반응기로부터 조혈 세포를 수확하는 단계로 이루어지는 것을 특징으로 하는 방법.
  8. 제7항에 있어서, 상기 조혈세포의 표면에서 약0.1 다인/㎠보다 큰 전단 응력을 유발하는 관류율의 사용을 포함하는 것을 특징으로 하는 방법.
  9. 제1항에 있어서, 상기 세포조성물을 유전자 전달벡터의 존재하에 배양하는 단계와, 안정한 유전적으로 형질전환된 사람 간세포를 얻는 단계를 포함하는 것을 특징으로 하는 방법.
  10. 제9항에 있어서, 상기 배지가 연속적으로 교체되는 것을 특징으로 하는 방법.
  11. 제10항에 있어서, 상기 배지의 교체가 상기 사람 간세포 덩어리의 최소한 일부분을 통하여 새로운 배지를 관류시키는 것을 특징으로 하는 방법.
  12. 제9항에 있어서, 상기 배지가 주기적으로 교체되는 것을 특징으로 하는 방법.
  13. 제12항에 있어서, 상기 배지의 교체가 상기 사람 간세포 덩어리의 최소한 일부분을 통하여 새로운 배지를 관류시키는 것을 특징으로 하는 방법.
  14. 제9항에 있어서, 상기 배지가 조혈배양 배지이고, 사람 말초혈액 단핵세포, 사람골수세포, 사람태아 간(liver)세포, 배 간 세포 및 사람 코오드 혈액세포로 이루어지는 군으로부터 선택된 최소한 한가지가 배양되는 것을 특징으로 하는 방법.
  15. 제9항에 있어서, 상기 세포조성물이 상기 간세포에 대하여 부화되는 것을 특징으로 하는 방법.
  16. 제9항에 있어서, 상기 배양된 사람 간 세포가 안정한 유전적으로 형질 전환된 사람 선구세포를 생산하는 것을 특징으로 하는 방법.
  17. 제9항에 있어서, 상기 배양된 사람 간 세포가 안정한, 유전적으로 형질 전환된 사람 선구 세포를 생산하는 것을 특징으로 하는 방법.
  18. 제9항에 있어서, IL-3 및 GM-CSF가 각각 0.1 내지 100ng ml-1일-1의 비율로 상기 배지에 연속적으로 첨가되는 것을 특징으로 하는 방법.
  19. 제18항에 있어서, 비만 세포 성장인자가 1 내지 100ng ml-1일-1의 비율로 상기 배지에 첨가되거나, IL-1 α가 상기 배지에 10 내지 100U ml-1/3 내지 5일 주기의 비율로 첨가되는 것을 특징으로 하는 방법.
  20. 제19항에 있어서, 비만 세포 성장 인자가 상기 배지에 첨가되는 것을 특징으로 하는 방법.
  21. 제19항에 있어서, IL-1α가 상기 배지에 첨가되는 것을 특징으로 하는 방법.
  22. 제19항에 있어서, 비만 세포 성장인자와 IL-α 두가지가 모두 상기 배지에 첨가되는 것을 특징으로 하는 방법.
  23. 제9항에 있어서, 상기 배지가 동물의 혈청 또는 혈장을 포함하는 것을 특징으로 하는 방법.
  24. 제9항에 있어서, 상기 배지가 코르티코스테로이드를 첨가하는 것을 특징으로 하는 방법.
  25. 제9항에 있어서, 상기 배지중의 글루코오스 농도를 5 내지 20mM의 범위로 락테이트 농도를 약 35mM 이하로, 글루타민 농도를 1 내지 3mM의 범위로, 그리고 암모니아 농도를 2.5mM이하로 유지시키는 것을 특징으로 하는 방법.
  26. 제14항에 있어서, 상기 배양물이 10-3내지 10-1(간질세포/총세포)의 양으로 사람 간질세포를 포함하는 것을 특징으로 하는 방법.
  27. 제9항에 있어서, 상기 유전자 전달벡터가 레트로바이러스인 것을 특징으로 하는 방법.
  28. 제9항에 있어서, 상기 사람 간세포를 레트로바이러스 팩키징 셀 라인 상징애그이 존재하에 배양하는 것을 포함하는 방법.
  29. 제9항에 있어서, 상기 사람 간세포를 레트로바이러스 팩키징 셀 라인 존재하에 배양하는 것을 포함하는 방법.
  30. 유전적으로 형질전환된 안전한 사람 간 세포.
  31. 제30항에 있어서, 상기 세포가 사람 골수에서 발견되는 사람 간 세포인 것을 특징으로 하는 유전적으로 형질전환된 안정한 사람 간 세포.
  32. 제30항에 있어서, 상기 세포가 사람 조혈 간세포인 것을 특징으로 하는 유전적으로 형질전환된 안정한 사람 간 세포.
  33. 제1항에 있어서, IL-3 및 GM-CSF가 상기 배지에 각각 0.1 내지 100ng ml-1일-1의 비율로 연속적으로 첨가되는 것을 특징으로 하는 방법.
  34. 제33항에 있어서, 상기 배지에, EpO가 0.001 내지 10U ml-1일-1의 비율로, 비만 성장 인자가 1 내지 100ng U ml-1일-1의 비율로, 또는 IL-1(α또는β)가 10 내지 100U ml-1/3 내지 5일 주기의 비율로 첨가되는 것을 특징으로 하는 방법.
  35. 제33항에 있어서, EpO가 상기 배지에 0.001 내지 10U ml-1일-1의 비율로 첨가되는 것을 특징으로 하는 방법.
  36. 제34항에 있어서, G-CSF, 기본 섬유아세포 성장인가, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, PDGF 및 EGF로 이루어지는 군으로부터 선택된 최소한 한 가지가 상기 배지에 첨가되는 것을 특징으로 하는 방법.
  37. 제1항에 있어서, 상기 배지가 동물의 혈청 또는 혈장을 포함하는 것을 특징으로 하는 방법.
  38. 제1항에 있어서, 상기 배지가 코르티코스테로이드를 포함하는 것을 특징으로 하는 방법.
  39. 제1항에 있어서, 상기 배지중의 글루코오스 농도를 5 내지 20mM의 범위로, 락테이트 농도를 약 35mM 이하로, 글루타민 농도를 1 내지 3mM의 범위로, 그리고 암모니아 농도를 2.5mM이하로 유지시키는 것을 포함하는 방법.
  40. 제6항에 있어서, 상기 배양물이 10-3내지 10-1(간질세포/총 세포)의 양으로 사람 골수 간질 세포를 포함하는 것을 특징으로 하는 방법.
  41. 제1항에 있어서, 팽창된 사람 간 세포 푸울을 얻는 것을 포함하는 방법.
  42. 제41항에 있어서, 팽창된 사람 조혈 간 세포 푸울을 얻는 것을 포함하는 방법.
  43. 제1항에 있어서, 사람 조혈 선구 세포를 배양하는 것을 포함하는 방법.
  44. 제43항에 있어서, 세포 조성물이 상기 사람 조혈 선구 세포에 대하여 부화된 것을 특징으로 하는 방법.
  45. 제43항에 있어서, IL-3 및 GM-CSF가 각각 0.1 내지 100ng ml-1일-1의 비율로 상기 배지에 연속적으로 첨가되는 것을 특징으로 하는 방법.
  46. 제45항에 있어서, 상기 배지에, EpO가 0.001 내지 10U ml-1일-1의 비율로, 비만 성장 인자가 1 내지 100ng U ml-1일-1의 비율로, 또는 IL-1(α또는β)가 10 내지 100U ml-1/3 내지 5일 주기의 비율로 첨가되는 것을 특징으로 하는 방법.
  47. 제6항에 있어서, 그로써 적혈구를 함유하는 세포 배양물이 얻어지는 것을 특징으로 하는 방법.
  48. 제6항에 있어서, 그로써 과립구를 함유하는 세포 배양물이 얻어지는 것을 특징으로 하는 방법.
  49. 제40항에 있어서, 그 결과 상기 사람 간질 세포의 대사 또는 GM-CSF 분비 또는 IL-6 분비가 증가되는 것을 특징으로 하는 방법.
  50. 제49항에 있어서, 상기 사람 간질 세포가 사람 골수 간질 세포인 것을 특징으로 하는 방법.
  51. 반응기 챔버; 상기 반응기 챔버로부터 영양배지를 도입하고 제거하기 위한 수단 및 상기 챔버로부터의 유출물을 모니터링하기 위한 수단; 최소한 그것의 일부가 형질전환되어, 상기 조혈세포의 증식, 분화, 또는 이들 2가지 모두를 특징하는 최소한 하나의 성장인자를 분비할 수 있도록, 상기 반응기 챔버내에서, 간세포를 포함하고 있는 사람 조혈 세포가 채워진 팩킹에 점착하는 간질세포로 이루어지는 생물학적 반응기.
  52. 선구 조혈 세포의 증식, 분화, 또는 이들 2가지를 모두 특징하는 최소한 하나의 사람 성장인자를 배출할 수 있는 형태로 발현할 수 있는 DNA 발현 구조물을 포함하고 있는 형질 전환된 섬유아세포.
  53. 정상 세포로부터 조혈 신생세포를 분리하는 방법으로서, 조혈세포의 세포 집단을, 한정된 이동성을 가지는 간질세포와 조합시켜 상기 조혈세포를 상기 간질세포와 접촉시키는 단계와, 정상세포의 유의할 만한 제거없이 상기 간질 세포와의 접촉으로부터 신생 세포를 제거하기에 충분한 힘을 생성하는 유체 흐름을 상기 조혈 세포에 적용하는 단계로 이루어지는 방법.
  54. 제1항에 있어서, 상기 배양물로부터 성숙한 세포를 제거하는 것을 포함하는 방법.
  55. 제42항에 있어서, 상기 배양물로부터 성숙한 세포를 제거하는 것을 포함하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930701843A 1990-12-17 1991-12-17 사람 간세포-함유 조성물의 배양방법 및 형질전환 방법 KR100225307B1 (ko)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US62834390A 1990-12-17 1990-12-17
US07/628,343 1990-12-17
US7/628,343 1990-12-17
US73702491A 1991-07-15 1991-07-15
US07/737,024 1991-07-29
US7/737,024 1991-07-29
US07/740,590 1991-08-05
US07/740,590 US5399493A (en) 1989-06-15 1991-08-05 Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US7/740,590 1991-08-05
PCT/US1991/009173 WO1992011355A1 (en) 1990-12-17 1991-12-17 Method for culturing and transforming human stem cell-containing compositions

Publications (2)

Publication Number Publication Date
KR930703434A true KR930703434A (ko) 1993-11-30
KR100225307B1 KR100225307B1 (ko) 1999-10-15

Family

ID=27417447

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701843A KR100225307B1 (ko) 1990-12-17 1991-12-17 사람 간세포-함유 조성물의 배양방법 및 형질전환 방법

Country Status (9)

Country Link
US (2) US5399493A (ko)
EP (2) EP0575350B1 (ko)
JP (5) JPH06505151A (ko)
KR (1) KR100225307B1 (ko)
AT (1) ATE295412T1 (ko)
AU (1) AU687674B2 (ko)
CA (1) CA2100268C (ko)
DE (1) DE69133459T2 (ko)
WO (1) WO1992011355A1 (ko)

Families Citing this family (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2060942T3 (es) * 1989-02-02 1994-12-01 Joel S Greenberger Terapia genetica utilizando celulas estromicas.
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
US5605822A (en) * 1989-06-15 1997-02-25 The Regents Of The University Of Michigan Methods, compositions and devices for growing human hematopoietic cells
US5635386A (en) * 1989-06-15 1997-06-03 The Regents Of The University Of Michigan Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
US5635387A (en) * 1990-04-23 1997-06-03 Cellpro, Inc. Methods and device for culturing human hematopoietic cells and their precursors
US5612211A (en) * 1990-06-08 1997-03-18 New York University Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors
DE69129113T2 (de) * 1990-06-08 1998-10-15 Univ New York Stimulierung der stroma- und vorläuferzellen im knochenmark
US20030125519A1 (en) 1990-08-27 2003-07-03 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
US5744361A (en) * 1991-04-09 1998-04-28 Indiana University Expansion of human hematopoietic progenitor cells in a liquid medium
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
AU685743B2 (en) * 1992-03-04 1998-01-29 Regents Of The University Of Michigan, The Methods, compositions and devices for maintaining and growing human stem and/or hematopoietic cells
SG47041A1 (en) * 1992-03-23 1998-03-20 Bender James G In vitro-derived human neutrophil precursor cells
US6001803A (en) * 1992-04-23 1999-12-14 Sloan-Kettering Institute For Cancer Research Composition of c-kit ligand, GM-CSF, and TNF-α and method of use
CA2133982C (en) * 1992-04-23 2008-02-12 Peter Besmer Ligand for the c-kit receptor and methods of use thereof
GB9308271D0 (en) 1993-04-21 1993-06-02 Univ Edinburgh Method of isolating and/or enriching and/or selectively propagating pluripotential animal cells and animals for use in said method
NZ314644A (en) 1993-05-24 2000-11-24 Immunex Corp Use of flt3-ligands as a growth stimulator of stem cells in the transplantation of tissue
US5554512A (en) * 1993-05-24 1996-09-10 Immunex Corporation Ligands for flt3 receptors
US5846529A (en) * 1993-08-23 1998-12-08 Nexell Therapeutics, Inc. Infusion of neutrophil precursors for treatment of neutropenia
US6037174A (en) * 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
FR2709309B1 (fr) * 1993-08-25 1995-11-10 Centre Nat Rech Scient Compositions cellulaires, préparation et utilisations thérapeutiques.
US5534423A (en) * 1993-10-08 1996-07-09 Regents Of The University Of Michigan Methods of increasing rates of infection by directing motion of vectors
US5599705A (en) * 1993-11-16 1997-02-04 Cameron; Robert B. In vitro method for producing differentiated universally compatible mature human blood cells
US6190655B1 (en) 1993-12-03 2001-02-20 Immunex Corporation Methods of using Flt-3 ligand for exogenous gene transfer
JPH09511392A (ja) * 1994-02-09 1997-11-18 ユニシン・テクノロジーズ・インコーポレーテッド 高性能細胞培養バイオリアクターおよび方法
US5882918A (en) * 1995-08-08 1999-03-16 Genespan Corporation Cell culture incubator
US5622857A (en) * 1995-08-08 1997-04-22 Genespan Corporation High performance cell culture bioreactor and method
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
US6242417B1 (en) 1994-03-08 2001-06-05 Somatogen, Inc. Stabilized compositions containing hemoglobin
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
EP0698085A4 (en) * 1994-03-11 1996-08-21 Baxter Int CONTINUOUS FLOW BIOREACTOR WITH CELL RETENTION GROOVES
US5512480A (en) * 1994-03-11 1996-04-30 Baxter International Inc. Flow-through bioreactor with grooves for cell retention
US7083979B1 (en) * 1994-03-25 2006-08-01 Indiana University Foundation Methods for enhanced retroviral-mediated gene transfer
DE4422667A1 (de) * 1994-06-30 1996-01-04 Boehringer Ingelheim Int Verfahren zur Herstellung und Züchtung hämatopoetischer Vorläuferzellen
US5811274A (en) * 1994-12-09 1998-09-22 The Regents Of The University Of Michigan Methods, compositions and apparatus for cell transfection
AU4419396A (en) * 1994-12-09 1996-06-26 Suzanne Gartner System for the maintenance, growth and differentiation of human and non-human primate pluripotent stem, progenitor and mature bone marrow cells
FR2728584A1 (fr) * 1994-12-22 1996-06-28 Centre Nat Rech Scient Procede de transfert de gene dans des cellules activees a partir d'un etat de repos
US6974571B2 (en) * 1995-03-28 2005-12-13 Thomas Jefferson University Isolated stromal cells and methods of using the same
US5719058A (en) * 1995-04-10 1998-02-17 Merck & Co., Inc. Method for producing a highly enriched population of osteoclast cells
US6121042A (en) * 1995-04-27 2000-09-19 Advanced Tissue Sciences, Inc. Apparatus and method for simulating in vivo conditions while seeding and culturing three-dimensional tissue constructs
US5792603A (en) * 1995-04-27 1998-08-11 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, storing, shipping and testing tissue, synthetic or native, vascular grafts
US5846828A (en) * 1995-06-07 1998-12-08 Advanced Tissue Sciences Apparatus and method for sterilizing, seeding, culturing, storing, shipping, and testing tissue, synthetic, or mechanical heart valves orvalve segments
US5876956A (en) * 1995-05-15 1999-03-02 Johns Hopkins University School Of Medicine Methods for identification or purification of cells containing an enzymatic intracellular marker
US5674750A (en) * 1995-05-19 1997-10-07 T. Breeders Continuous selective clonogenic expansion of relatively undifferentiated cells
US5925567A (en) 1995-05-19 1999-07-20 T. Breeders, Inc. Selective expansion of target cell populations
WO1996039992A1 (en) * 1995-06-07 1996-12-19 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, storing, shipping, and testing replacement cartilage tissue constructs
US5688687A (en) * 1995-06-07 1997-11-18 Aastrom Biosciences, Inc. Bioreactor for mammalian cell growth and maintenance
US5843766A (en) * 1995-06-07 1998-12-01 Advanced Tissue Sciences, Inc. Apparatus for the growth and packaging of three dimensional tissue cultures
US5728581A (en) * 1995-06-07 1998-03-17 Systemix, Inc. Method of expanding hematopoietic stem cells, reagents and bioreactors for use therein
GB9518606D0 (en) 1995-09-12 1995-11-15 Inst Of Psychiatry Neural transplantation
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US6060052A (en) 1995-10-30 2000-05-09 Systemix, Inc. Methods for use of Mpl ligands with primitive human hematopoietic stem cells
US6991787B1 (en) 1995-12-29 2006-01-31 Alg Company Methods of preparing bone marrow stromal cells for use in gene therapy
US5766950A (en) * 1995-12-29 1998-06-16 Alg Company Expansion of bone marrow stromal cells
US5763267A (en) * 1996-04-16 1998-06-09 Advanced Tissue Sciences Apparatus for the large scale growth and packaging of cell suspensions and three-dimensional tissue cultures
US6165785A (en) * 1996-05-24 2000-12-26 University Of Cincinnati Bone marrow cultures for developing suppressor and stimulator cells for research and therapeutic applications
US6383480B1 (en) * 1996-07-10 2002-05-07 Meiji Milk Products, Co., Ltd. Composition comprising midkine or pleiotrophin protein and method of increasing hematopoietic cells
US6458585B1 (en) 1996-08-14 2002-10-01 Nexell Therapeutics Inc. Cytokine-free culture of dendritic cells
ATE449851T1 (de) 1996-10-01 2009-12-15 Geron Corp Menschlicher telomerase reverse transcriptase promoter
US6331406B1 (en) 1997-03-31 2001-12-18 The John Hopkins University School Of Medicine Human enbryonic germ cell and methods of use
US6090622A (en) * 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
AU7481098A (en) * 1997-05-13 1998-12-08 Case Western Reserve University Osteoarthritis cartilage regeneration using human mesenchymal stem ce lls
US20020034819A1 (en) * 1998-02-23 2002-03-21 Alan K. Smith Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
US6835377B2 (en) 1998-05-13 2004-12-28 Osiris Therapeutics, Inc. Osteoarthritis cartilage regeneration
US6255112B1 (en) * 1998-06-08 2001-07-03 Osiris Therapeutics, Inc. Regulation of hematopoietic stem cell differentiation by the use of human mesenchymal stem cells
AUPP421298A0 (en) * 1998-06-19 1998-07-09 Fertilitescentrum Ab Method and medium for in vitro culture of human embryos
WO2000011139A1 (en) * 1998-08-24 2000-03-02 T.Breeders, Inc. Cell population containing non-fetal hemangioblasts and method for producing same
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
CA2385628A1 (en) * 1999-09-27 2001-04-05 Ammon B. Peck Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US6429224B1 (en) * 1999-12-06 2002-08-06 Rhode Island Hospital, A Lifespan Partner Use of taurolidine to treat tumors
US6682902B2 (en) 1999-12-16 2004-01-27 Schering Aktiengesellschaft DNA encoding a novel RG1 polypeptide
JP5090604B2 (ja) * 2000-04-25 2012-12-05 オシリス セラピューティクス，インコーポレイテッド 動物の関節修復のための医薬組成物調製への間葉幹細胞の使用法
US6828145B2 (en) 2000-05-10 2004-12-07 Cedars-Sinai Medical Center Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker
NL1017973C2 (nl) * 2000-05-10 2002-11-08 Tristem Trading Cyprus Ltd Inrichting.
EP1167517A1 (en) * 2000-06-22 2002-01-02 IsoTis N.V. Tissue engineering
AU2001280334B2 (en) * 2000-06-28 2005-05-05 Ascendia Ab DNA/rna-embedding medium and method of use
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
KR100915482B1 (ko) 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP1362095B1 (en) * 2001-02-14 2015-05-27 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
WO2002081620A1 (fr) * 2001-04-03 2002-10-17 Kabushiki Kaisya Advance Systemes de culture cellulaire tridimensionnelle
US7129034B2 (en) * 2001-10-25 2006-10-31 Cedars-Sinai Medical Center Differentiation of whole bone marrow
CA2470853A1 (en) * 2001-12-13 2003-06-19 Japan Science And Technology Agency Human cell culture medium and culture method
CA2477411A1 (en) * 2002-03-02 2003-09-12 Board Of Regents, The University Of Texas Local production and/or delivery of anti-cancer agents by stromal cell precursors
US20040076617A1 (en) * 2002-03-18 2004-04-22 Lieber Jonathan Gregory Method for production of neutrophils and uses therefor
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
DE60334453D1 (de) * 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
US7838290B2 (en) * 2002-07-25 2010-11-23 The Scripps Research Institute Hematopoietic stem cells and methods of treatment of neovascular eye diseases therewith
EP1571910A4 (en) 2002-11-26 2009-10-28 Anthrogenesis Corp CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE
NZ542127A (en) * 2003-02-13 2008-04-30 Anthrogenesis Corp Use of umbilical cord blood to treat individuals having a disease, disorder or condition
US20050003533A1 (en) * 2003-05-08 2005-01-06 Pawel Kalinski Mature type-1 polarized dendritic cells with enhanced IL-12 production and methods of serum-free production and use
US20050023085A1 (en) * 2003-07-30 2005-02-03 Munton Timothy John Lifesaver apparatus
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
EP1711618B1 (en) 2003-12-23 2010-08-04 Mount Sinai Hospital Corporation Methods for detecting markers associated with endometrial disease or phase
US20070037276A1 (en) 2004-02-23 2007-02-15 Eudes Francois Marie De Crecy Continuous culture apparatus with mobile vessel, allowing selection of fitter cell variants and producing a culture in a continuous manner
CA2566561C (en) * 2004-06-04 2013-01-08 Universite Pierre Et Marie Curie - Paris Vi A method for producing red blood cells
EP1773981A1 (en) * 2004-07-12 2007-04-18 Sorin Group Italia S.R.L. Device and method for growing human cells
US20060035375A1 (en) * 2004-08-16 2006-02-16 Head Jonathan F Method for selectively culturing epithelial or carcinoma cells
US7989001B2 (en) * 2004-09-13 2011-08-02 Untae Kim Method of separating tumor cells with and without lymphotropic metastatic potential in a human carcinoma
ATE373081T1 (de) 2004-09-30 2007-09-15 Reneuron Ltd Zelllinie
WO2006052960A2 (en) * 2004-11-08 2006-05-18 The General Hospital Corporation METHODS AND COMPOSITIONS FOR INCREASING STEM CELL HOMING USING Gαs ACTIVATORS
AU2006243800B2 (en) 2005-05-04 2012-02-02 Commonwealth Scientific And Industrial Research Organisation Selecting, culturing and creating lineage committed hematopoietic stem cells
ES2452595T3 (es) 2005-10-13 2014-04-02 Anthrogenesis Corporation Inmunomodulación usando células madre de la placenta
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
AU2006315601A1 (en) * 2005-11-14 2007-05-24 Enterprise Partners Venture Capital Stem cell factor therapy for tissue injury
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
PL2471904T3 (pl) 2005-12-29 2019-08-30 Celularity, Inc. Populacje komórek macierzystych łożyska
US8455250B2 (en) 2005-12-29 2013-06-04 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
US7682822B2 (en) 2006-03-31 2010-03-23 Aastrom Biosciences, Inc. Ex vivo generated tissue system
US20080050814A1 (en) * 2006-06-05 2008-02-28 Cryo-Cell International, Inc. Procurement, isolation and cryopreservation of fetal placental cells
WO2007146106A2 (en) * 2006-06-05 2007-12-21 Cryo- Cell International, Inc. Procurement, isolation and cryopreservation of maternal placental cells
CA2655990A1 (en) * 2006-06-22 2007-12-27 Tai June Yoo Restoration of hearing loss
EP2054500B1 (en) 2006-08-18 2016-11-23 Ajinomoto Co., Inc. An l-glutamic acid producing bacterium and a method for producing l-glutamic acid
EP2061871A1 (en) * 2006-09-14 2009-05-27 ProBioGen AG Modular culture system for maintenance, differentiation and proliferation of cells
DK2086556T3 (da) 2006-11-03 2011-05-09 Aastrom Biosciences Inc Populationer af blandede celler til vævsreparation og separationsteknik til cellebehandling
WO2008097927A2 (en) * 2007-02-06 2008-08-14 Tai June Yoo Treatment and prevention of neurodegenerative diseases using gene therapy
AU2008216749B2 (en) 2007-02-12 2014-03-13 Celularity Inc. Treatment of inflammatory diseases using placental stem cells
EP2129775A1 (en) 2007-02-12 2009-12-09 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and cd34+, cd45- placental stem cell-enriched cell populations
WO2008121461A2 (en) * 2007-02-26 2008-10-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vaccine for activating helper function of cd8+ tcells
WO2008109668A2 (en) * 2007-03-05 2008-09-12 Caridianbct, Inc. Methods to control cell movement in hollow fiber bioreactors
CA2680130C (en) * 2007-03-05 2016-01-12 Caridianbct, Inc. Cell expansion system and methods of use
JP5524824B2 (ja) * 2007-04-06 2014-06-18 テルモ ビーシーティー、インコーポレーテッド 改良されたバイオリアクタ表面
EP2148922B1 (en) * 2007-04-13 2020-03-04 Terumo BCT, Inc. Cell expansion system and methods of use
EP2783692B1 (en) 2007-09-28 2019-01-02 Celularity, Inc. Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
EP2209810A1 (en) * 2007-10-15 2010-07-28 King's College London Viral therapeutic
WO2009072635A1 (ja) * 2007-12-06 2009-06-11 Nissan Chemical Industries, Ltd. ヘテロ環化合物による造血幹細胞の増幅方法
US10059923B2 (en) 2008-01-30 2018-08-28 Memorial Sloan Kettering Cancer Center Methods for off-the-shelf tumor immunotherapy using allogeneic T-cell precursors
US10350243B2 (en) * 2008-01-30 2019-07-16 Memorial Sloan-Kettering Cancer Center Methods for off-the-shelf-tumor immunotherapy using allogeneic T-cell precursors
CA2618163A1 (en) 2008-02-07 2009-08-07 K. W. Michael Siu Head and neck cancer biomarkers
US8986702B2 (en) 2008-05-16 2015-03-24 Taiga Biotechnologies, Inc. Antibodies and processes for preparing the same
MX2011001990A (es) 2008-08-20 2011-03-29 Anthrogenesis Corp Composiciones mejoradas de celulas y metodos para preparar las mismas.
CN105796602A (zh) 2008-08-20 2016-07-27 人类起源公司 利用分离的胎盘细胞治疗中风
CN102176919A (zh) 2008-08-22 2011-09-07 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
CA2735522C (en) 2008-08-28 2017-04-18 Taiga Biotechnologies, Inc. Modulators of myc, methods of using the same, and methods of identifying agents that modulate myc
WO2010054271A1 (en) * 2008-11-06 2010-05-14 Indiana University Research & Technology Corporation Materials and methds to enhance hematopoietic stem cells engraftment procedures
KR20110086176A (ko) 2008-11-19 2011-07-27 안트로제네시스 코포레이션 양막 유래 부착성 세포
JP5737177B2 (ja) * 2009-06-04 2015-06-17 日産化学工業株式会社 ヘテロ環化合物及び造血幹細胞の増幅剤
JP2011045269A (ja) * 2009-08-26 2011-03-10 Hirosaki Univ 幹細胞および／または前駆細胞の培養方法
ES2646750T3 (es) 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
SI2556145T1 (sl) 2010-04-07 2017-01-31 Anthrogenesis Corporation Angiogeneza z uporabo placentnih matičnih celic
KR20130092394A (ko) 2010-04-08 2013-08-20 안트로제네시스 코포레이션 태반 줄기 세포를 사용한 사르코이드증의 치료
WO2011140231A1 (en) 2010-05-05 2011-11-10 Caridianbct, Inc. Method of reseeding adherent cells grown in a hollow fiber bioreactor system
NZ605505A (en) 2010-07-13 2015-02-27 Anthrogenesis Corp Methods of generating natural killer cells
WO2012021969A1 (en) 2010-08-16 2012-02-23 Mount Sinai Hospital Markers of the male urogenital tract
EP2625264B1 (en) 2010-10-08 2022-12-07 Terumo BCT, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
AR093183A1 (es) 2010-12-31 2015-05-27 Anthrogenesis Corp Aumento de la potencia de celulas madre de placenta usando moleculas de arn moduladoras
EP3443968A1 (en) 2011-06-01 2019-02-20 Celularity, Inc. Treatment of pain using placental stem cells
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
UA114796C2 (uk) 2011-09-30 2017-08-10 Блубьод Байо, Інк. Спосіб підвищення ефективності трансдукції
CA2863795A1 (en) 2012-02-13 2013-08-22 Gamida-Cell Ltd. Culturing of mesenchymal stem cells
US8940294B2 (en) 2012-03-02 2015-01-27 Tissuetech, Inc. Methods of isolating and culturing stem cells
HUE053247T2 (hu) 2012-05-09 2021-06-28 Cantex Pharmaceuticals Inc Mieloszuppresszió kezelése
JP6329537B2 (ja) * 2012-07-11 2018-05-23 サンガモ セラピューティクス， インコーポレイテッド 生物学的薬剤の送達のための方法および組成物
AU2013292330B2 (en) 2012-07-20 2018-07-12 Taiga Biotechnologies, Inc. Enhanced reconstitution and autoreconstitution of the hematopoietic compartment
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
CN104540933A (zh) 2012-08-20 2015-04-22 泰尔茂比司特公司 在细胞扩增系统的生物反应器中加载和分配细胞的方法
AU2014215458A1 (en) 2013-02-05 2015-08-13 Anthrogenesis Corporation Natural killer cells from placenta
US9365825B2 (en) 2013-03-11 2016-06-14 Taiga Biotechnologies, Inc. Expansion of adult stem cells in vitro
US10272115B2 (en) 2013-03-11 2019-04-30 Taiga Biotechnologies, Inc. Production and use of red blood cells
WO2015073913A1 (en) 2013-11-16 2015-05-21 Terumo Bct, Inc. Expanding cells in a bioreactor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
WO2015164808A1 (en) 2014-04-24 2015-10-29 Terumo Bct, Inc. Measuring flow rate
US20160090569A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled Feed
US10052346B2 (en) 2015-02-17 2018-08-21 Cantex Pharmaceuticals, Inc. Treatment of myelodysplastic syndromes with 2-O and,or 3-O desulfated heparinoids
US20160243168A1 (en) * 2015-02-17 2016-08-25 Cantex Pharmaceuticals, Inc. Adoptive cell transfer methods
JP6962563B2 (ja) * 2015-05-12 2021-11-05 株式会社オンチップ・バイオテクノロジーズ 単一粒子解析方法およびその解析のためのシステム
GB201508752D0 (en) 2015-05-21 2015-07-01 Mason Christopher And Veraitch Farlan S Cell culture device, system and methods of use thereof
DK3313982T3 (da) * 2015-06-23 2023-12-11 Univ Texas Fremgangsmåder og indretning til konditionering af cellepopulationer til celleterapier
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN108138130A (zh) 2015-08-31 2018-06-08 爱平世股份有限公司 多能干细胞制造系统和生产诱导多能干细胞的方法
WO2017061528A1 (ja) * 2015-10-09 2017-04-13 国立大学法人名古屋大学 血小板製造用デバイス、血小板製造装置及び血小板製造方法
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
JP6965874B2 (ja) * 2016-03-28 2021-11-10 ソニーグループ株式会社 細胞培養方法
WO2017191691A1 (ja) 2016-05-02 2017-11-09 インテグリカルチャー株式会社 成長誘導システム、成長誘導制御装置、成長誘導制御方法、および、成長誘導制御プログラム
JP6111510B1 (ja) 2016-05-02 2017-04-12 インテグリカルチャー株式会社 成長誘導システム、成長誘導制御装置、成長誘導制御方法、および、成長誘導制御プログラム
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US10583156B2 (en) 2016-12-02 2020-03-10 Taiga Biotechnologies, Inc. Nanoparticle formulations
US11629332B2 (en) 2017-03-31 2023-04-18 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US10149898B2 (en) 2017-08-03 2018-12-11 Taiga Biotechnologies, Inc. Methods and compositions for the treatment of melanoma
US20210017467A1 (en) * 2018-03-30 2021-01-21 Dsm Ip Assets B.V. Method of reducing emulsion by broth washing

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481946A (en) * 1980-08-14 1984-11-13 Altshuler John H Bone marrow transplant method and apparatus
US4486188A (en) * 1980-08-14 1984-12-04 Applied Medical Devices, Inc. Bone marrow transplant method and apparatus
US4514499A (en) * 1983-02-04 1985-04-30 Corning Glass Works Cell culture using a monolithic support
US4963489A (en) * 1987-04-14 1990-10-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5032407A (en) * 1987-01-16 1991-07-16 Ohio University Edison Animal Biotechnology Center Gene transfer using transformed, neodetermined, embryonic cells
US5399493A (en) * 1989-06-15 1995-03-21 The Regents Of The University Of Michigan Methods and compositions for the optimization of human hematopoietic progenitor cell cultures
KR100196062B1 (ko) * 1989-06-15 1999-06-15 로버트 에프. 게이민 세포를 성장시키기 위한 방법, 조성물 및 장치
US5061620A (en) * 1990-03-30 1991-10-29 Systemix, Inc. Human hematopoietic stem cell
US5199942A (en) * 1991-06-07 1993-04-06 Immunex Corporation Method for improving autologous transplantation
NL9101680A (nl) * 1991-10-04 1993-05-03 Tno Werkwijze voor het genetisch modificeren van beenmergcellen van primaten, alsmede daarbij bruikbare cellen die recombinante retrovirale vectoren produceren.
WO1993018137A1 (en) * 1992-03-04 1993-09-16 Systemix, Inc. Culturing of hematopoietic stem cells and their genetic engineering
WO1993018136A1 (en) * 1992-03-05 1993-09-16 Cytomed, Inc. Process for supporting hematopoietic progenitor cells
CA2170980A1 (en) * 1993-09-03 1995-03-09 James Mule Genetically modified human hematopoietic stem cells and their progeny

Also Published As

Publication number Publication date
AU9175091A (en) 1992-07-22
DE69133459T2 (de) 2006-01-19
AU5059296A (en) 1996-07-11
EP1473360A3 (en) 2005-02-02
ATE295412T1 (de) 2005-05-15
EP0575350B1 (en) 2005-05-11
JP2000189157A (ja) 2000-07-11
EP0575350A1 (en) 1993-12-29
JP2001120261A (ja) 2001-05-08
DE69133459D1 (de) 2005-06-16
JPH06505151A (ja) 1994-06-16
CA2100268C (en) 2008-12-02
AU665525B2 (en) 1996-01-11
CA2100268A1 (en) 1992-06-18
WO1992011355A1 (en) 1992-07-09
EP1473360A8 (en) 2010-07-28
KR100225307B1 (ko) 1999-10-15
AU687674B2 (en) 1998-02-26
JP2006158401A (ja) 2006-06-22
US5670351A (en) 1997-09-23
JPH11221074A (ja) 1999-08-17
EP1473360A2 (en) 2004-11-03
EP0575350A4 (en) 1997-07-02
US5399493A (en) 1995-03-21

Similar Documents

Publication Publication Date Title
KR930703434A (ko) 사람 간세포-함유 조성물의 배양방법 및 형질전환 방법
Bagley et al. Extended culture of multipotent hematopoietic progenitors without cytokine augmentation in a novel three-dimensional device
US20180250344A1 (en) Lithium stimulation of cord blood stem cell proliferation and growth factor production
DE69533223D1 (de) Zusammensetzungen und verfahren zur stimulierung der proliferation und der differenzierung von menschlichen fetalen und erwachsenen pankreatischen zellen ex vivo
US20210095256A1 (en) Method and system for 3d cell culture and use thereof
Takahashi et al. Methods for generating vascularized islet‐like organoids via self‐condensation
JPH09501324A (ja) 細胞保持用の溝を備えた貫流バイオリアクター
CN109430252A (zh) 一种干细胞冻存液及其制作方法
Pierson et al. Production of human natural killer cells for adoptive immunotherapy using a computer-controlled stirred-tank bioreactor
CA2725196A1 (en) Method of differentiating mammalian progenitor cells into insulin producing pancreatic islet cells
Aiuti et al. Hematopoietic Support and Cytokine Expression of Murine–Stable Hepatocyte Cell Lines (Mmh)
EP1743024B1 (en) Method of expanding cord blood cells
Ehrlich et al. Artificial capillary perfusion cell culture: metabolic studies
EP3406704B1 (en) Modification method for adhesion-state cell culture
Albright et al. In vitro growth of Trypanosoma musculi in cellfree medium conditioned by rodent macrophages and mercaptoethanol
Warnock et al. Packed bed bioreactors
Shayan et al. A non-rotational, computer-controlled suspension bioreactor for expansion of umbilical cord blood mononuclear cells
Khong et al. Stromalized microreactor supports murine hematopoietic progenitor enrichment
TWI776368B (zh) 細胞分化培養基組合物、高分泌量胰島素產生細胞及其製備方法
Shakhov et al. In vitro formation of mesenchymal bone marrow islets
JPH09107955A (ja) 動物細胞培養用培地
US20090208918A1 (en) Methods and devices for ex-vivo maintenance of bone marrow, hematopoiesis and blood cell production
Phillips et al. Genetic factors influencing murine hematopoietic productivity in culture
CN117925521A (en) NK cell activator for culture and application thereof
Koller et al. Tissue engineering of bone marrow

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
A107 Divisional application of patent
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20100719

Year of fee payment: 12

LAPS Lapse due to unpaid annual fee